Trial Profile
A Trial of CTS-1027 in Interferon-Naive Hepatitis C Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs CTS 1027 (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Conatus Pharmaceuticals
- 27 Feb 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
- 04 Aug 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.